APCs Therapy in Combination with KynA

AI-001: A One-Time Delivery of Antigen-Presenting Cells and Systemic KynA Administration for Synergistic Immunomodulation, Effectively Halting Autoimmune Responses.”

KynA and APCs are systemically administered to the patient via oral and intraperitoneal injection respectively.

Innovative Antigen-Presenting Cell Therapy Combined with Kynurenic Acid (KynA) for Autoimmune Diseases

AI-001 is a groundbreaking first-generation candidate for autoimmune therapy.  As our proprietary treatment to reverse a subset of clinical autoimmune conditions, AI-001 is uniquely designed to involve a single, one-time injection of APCs combined with daily administration of KynA. This innovative approach leverages the benefits of antigen-presenting cell therapy in combination with the immune-modulating properties of kynurenic acid, offering a promising, synergistic improvement in reversing certain autoimmune conditions that is far greater than either therapy has been able to accomplish separately. Our research has demonstrated that AI-001 can effectively reinstate immune tolerance and reduce autoreactivity, leading to the potential remission of some clinical autoimmune conditions.

Impact of Our Therapy on Targeted Diseases

AI-001 therapy has significant therapeutic effects on Type 1 Diabetes (T1D), demonstrating a marked decrease in blood glucose levels over an extended period of time even after kynurenine injections were stopped, as compared to controls where APCs or kynurenine alone were administered or where there was no treatment.  In effect, AI-001 administration synergistically reinstated immune tolerance and reduced autoreactivity, leading to remission of autoimmune diabetes in our subjects.

AI-001 therapy in our subjects demonstrated a significant decrease in hair loss over an extended period of time.   After 120 days in control and treated groups, untreated subjects showed sever hair loss, while those receiving kynurenine or APCs alone showed some hair growth.  In contrast, those that were administered AI-001 exhibited complete hair coverage or only slight hair loss.